Search - tctmd.com

Displaying 341 - 360 of 570

Sort: Relevancy | Date

What is the Role of LVADs for BTR?

Presentation THT 2022

What is the Role of LVADs for BTR?

Presenter: Stavros Drakos

February 01, 2022

Exercise Limitations in LVAD Patients

Presentation THT 2022

Exercise Limitations in LVAD Patients

Presenter: Donna Mancini

February 01, 2022

The Changing Role of LVADs Within the Current UNOS Allocation System -- Regionality

Presentation THT 2022

The Changing Role of LVADs Within the Current UNOS Allocation System -- Regionality

Presenter: Veli Topkara

February 01, 2022

February 2022 News Roundup

News Opinion CV Team Dispatch

February 2022 News Roundup

February 01, 2022

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

January 26, 2022

Cardiac Abnormalities Seen After COVID-19, but Recovery Is Quick

News Daily News

Cardiac Abnormalities Seen After COVID-19, but Recovery Is Quick

Michael O'Riordan

January 20, 2022

Extended DANISH Follow-up Supports ICD Benefits in Younger Nonischemic HF Patients

News Daily News

Extended DANISH Follow-up Supports ICD Benefits in Younger Nonischemic HF Patients

December 14, 2021

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

News Conference News PCR London Valves 2021

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

Michael O'Riordan

November 26, 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

AccuCinch: Outcomes of Transcatheter LV Volume Reduction in HFrEF With a Transcatheter Ventricular Restoration System

Presentation TCT 2021

AccuCinch: Outcomes of Transcatheter LV Volume Reduction in HFrEF With a Transcatheter Ventricular Restoration System

Presenter: Ulrich Jorde

November 06, 2021

LV Reconstruction II: Bioventrix

Presentation TCT 2021

LV Reconstruction II: Bioventrix

Presenter: Gregg Stone

November 06, 2021

LV Reconstruction I: Ancora

Presentation TCT 2021

LV Reconstruction I: Ancora

Presenter: Nadira Hamid

November 06, 2021

Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines

News Daily News

Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines

October 06, 2021

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

September 20, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.